• 1
    Parkin DM,Bray FI,Devessa SS. Cancer burden for the year 2000: the global picture. Eur J Cancer. 2001; 37(Suppl 8): S4S66.
  • 2
    Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J. 1995; 311: 899909.
  • 3
    Ardizzoni A,Tiseo M,Boni L, et al. CISCA (cisplatin vs carboplatin) meta-analysis: an individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first line treatment of advanced non small cell lung cancer (NSCLC). Proc ASCO. 2005; 24: 7011.
  • 4
    Smith IE,Obrien MER,Talbot DC, et al. Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine and cisplatin. J Clin Oncol. 2001; 19: 13361343.
  • 5
    Socinski M,Schell MJ,Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIb/IV non-small cell lung cancer. J Clin Oncol. 2002; 20: 13351343.
  • 6
    Novello S,Bruzzi P,Barone A, et al. Phase III study in stage IV non small cell lung cancer (NSCLC) patients (pts) treated with two cycles of Cisplatin/Gemcitabine followed by a randomitazion to three additional cycles of the same combination or gemcitabine alone. Proc ASCO. 2005; 23: 7051.
  • 7
    Belani CP,Barstis J,Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 2003; 21: 29332939.
  • 8
    Belani CP,Perry MC,La Rocca RV, et al. Maintenance therapy (MT) with weekly paclitaxel improves outcome for advanced non-small cell lung cancer (NSCLC) patients. Proc ASCO. 2005; 23: 7143.
  • 9
    Brodowicz T,Krzakowski M,Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006; 52: 155163.
  • 10
    Edelman MJ,Gandara DR,Lau DH, et al. Sequential combination chemotherapy in patients with advanced non-small cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer. 2001; 92: 146152.
  • 11
    Edelman MJ,Clark JI,Chansky K, et al. Phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res. 2004; 10: 50225026.
  • 12
    Hosoe S,Komuta K,Shibata K, et al. Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02). Br J Cancer. 2003; 8: 342347.
  • 13
    Gandara D,Vokes E,Green M, et al. Activity of docetaxel in platinum-treated non-small cell lung cancer: results of a Phase II multicenter trial. J Clin Oncol. 2000; 18: 131135.
  • 14
    Lowe SW,Ruley HE,Jacks T,Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993; 74: 957967.
  • 15
    Safran H,King T,Choy H, et al. p53 mutations do not predict response to paclitaxel/radiation for non-small cell lung carcinoma. Cancer. 1996; 78: 12031210.
  • 16
    Bria E,Cuppone F,Ciccarese M, et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev. 2006; 32: 583587.
  • 17
    A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med. 2001; 20: 859866.
  • 18
    Alberola V,Camps C,Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol. 2003; 21: 32073213.
  • 19
    Scagliotti GV,De Marinis F,Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002; 21: 42854291.
  • 20
    Schiller JH,Harrington D,Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 2: 9298.
  • 21
    Gridelli C,Gallo C,Di Maio M, et al. A randomized clinical trial of two docetaxel regimens (weekly vs every 3 weekly) in the second-line treatment of nonsmall-cell lung cancer: the DISTAL 01 study. Br J Cancer. 2004; 91: 19962004.